Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New modality showdowns
Genetic therapies compete in the same indications, as degraders come of age
BioCentury | Jan 14, 2025
Deals
JPM ushers in flurry of biotech deals, headlined by J&J’s Intra-cellular buy
BioCentury’s Deals Report surveys deals by GSK, Idrx, Lilly, Scorpion, Lantheus, Telix, Gilead, Leo, CBC Group and more
BioCentury | Jan 13, 2025
Deals
JPM deal buzz & Rep. Auchincloss’ take on biopharma
J&J’s nearly $15B neuro buy kicks off biotech meeting. Plus: Washington insights and 2024’s key FDA approvals
BioCentury | Dec 30, 2024
Product Development
The uncertainty principle: Hello, 2025
BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025
BioCentury | Apr 10, 2024
Product Development
AACR roundup: BioNTech shows personalized neoantigen vaccines are durable
Plus: Readouts from Geneos, BMS and Nurix
BioCentury | Aug 8, 2023
Emerging Company Profile
Recludix: targeting STATs via their SH2 domains
San Diego company’s STAT6 program is partnered with Sanofi
BioCentury | Jul 21, 2023
Deals
July 20 Quick Takes: Via its second preclinical deal this week, Sanofi gains Recludix’s oral STAT6 inhibitor
Plus: Idorsia sells Japan, Korea business to Sosei and updates from Gossamer and BioNTech-Biotheus
BioCentury | Feb 18, 2022
Discovery & Translation
Engineered Wnt ligand restores BBB; plus Codiak, Autotac and more
BioCentury’s roundup of translational news
BioCentury | Dec 5, 2019
Tools & Techniques
Using exosomes to switch myeloid cells
Codiak’s exosome therapies against STAT6, CEBPB effectively switch macrophages to kill cancer
BioCentury | Jun 2, 2019
Company News
Aslan’s change of course on eczema asset brings flexibility for future deals
Items per page:
1 - 10 of 21